EFFICACY RESULTS OF 0.2.G/DAY FLUOCINOLONE ACETONIDE IMPLANT (FAC) IN DMO VITRECTOMISED PATIENTS

被引：0
|
作者：
Erginay, A. [1 ]
Habib, M. [2 ]
Goldsmith, C. [3 ]
Schmit-Eilenberger, V. [4 ]
Massin, P. [1 ,5 ]
机构：
[1] Lariboisiere Univ Hosp, AP HP, Paris, France
[2] Sunderland Eye Hosp, Sunderland, Tyne & Wear, England
[3] James Paget Univ Hosp, Great Yarmouth, Norfolk, England
[4] Karlsruhe Eye Clin, Karlsruhe, Germany
[5] Opthalm Clin Breteuil, Paris, France
来源：
EUROPEAN JOURNAL OF OPHTHALMOLOGY | 2016年 / 26卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E109 / E110
页数：2
相关论文
共 50 条
  • [31] Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
    Young, James F.
    Walkden, Andrew
    Stone, Amy
    Mahmood, Sajjad
    OPHTHALMOLOGY AND THERAPY, 2019, 8 (03) : 477 - 484
  • [32] Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®)
    Bahram Bodaghi
    Quan Dong Nguyen
    Glenn Jaffe
    Ramin Khoramnia
    Carlos Pavesio
    Journal of Ophthalmic Inflammation and Infection, 10
  • [33] Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 μg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema
    Pessoa, Bernardete
    Castro, Catarina
    Ferreira, Andre
    Leite, Joao
    Heitor, Joao
    Meneres, Pedro
    Figueira, Joao
    Meireles, Angelina
    Beirao, Joao Melo
    OPHTHALMIC RESEARCH, 2022, 65 (03) : 310 - 320
  • [34] Effects of Long-Term DME Control With 0.2 μg/Day Fluocinolone Acetonide Implant on Quality of Life: An Exploratory Analysis From the FAME Trial
    Singer, Michael A.
    Wykoff, Charles C.
    Grewal, Dilraj S.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2020, 51 (11): : 658 - 667
  • [35] Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema: 12 month results
    Pearson, P
    Baker, CW
    Eliott, D
    Ip, MS
    Morse, LS
    Callanan, D
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U489 - U489
  • [36] Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN(R))
    Bodaghi, Bahram
    Quan Dong Nguyen
    Jaffe, Glenn
    Khoramnia, Ramin
    Pavesio, Carlos
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2020, 10 (01)
  • [37] Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
    Steeples, Laura R.
    Pockar, Sasa
    Jones, Nicholas P.
    Leal, Ines
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 1433 - 1442
  • [38] FLUOCINOLONE ACETONIDE 0.2μg/DAY (ILUVIEN®) FOR THE TREATMENT OF CHRONIC DIABETIC MACULAR OEDEMA: AN ITALIAN REAL-WORLD EXPERIENCE
    Capone, L.
    Lattanzio, R.
    Bandello, F.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2019, 29 (03) : NP17 - NP17
  • [39] Treatment burden associated with intravitreal injections in the real world: PALADIN Phase 4 trial with fluocinolone acetonide 0.2 μg/day
    Singer, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [40] The effectiveness of the ILUVIEN® (0.2 μg per day of mg fluocinolone acetonide) implant in the treatment of non-infectious posterior uveitis-12-month outcomes from UAE
    Gurbaxani, Avinash
    Kozak, Igor
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
12345